FDA schedules advisory committee hearing for Lynparza prostate cancer application
What once appeared to be a slam dunk for Merck and AstraZeneca’s PARP inhibitor Lynparza may no longer be a sure thing.
The FDA will convene an advisory committee to discuss an application to further expand the drug’s label into a broader set of prostate cancer patients, the companies announced Thursday morning. The hearing, run by the Oncologic Drugs Advisory Committee, or ODAC, will take place on April 28.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.